Close Menu

Biodesix

Drugmaker Aveo Oncology and test developer Biodesix entered into a partnership last week in which the two will share more equally the risks and profits of developing a personalized medicine product.

Proteomic diagnostics firm Biodesix and drug developer Aveo Oncology said this week that they are partnering to co-develop and commercialize Aveo's non-small cell lung cancer antibody drug ficlatuzumab and Biodesix's Veristrat as a companion test to predict best responders.

NEW YORK (GenomeWeb News) – Aveo Oncology and Biodesix announced today an agreement to develop Aveo's investigational non-small cell lung cancer drug ficlatuzumab alongside Biodesix's VeriStrat serum protein test as a companion diagnostic.

Insurer Aetna last month released a clinical policy bulletin providing an assessment of various available molecular-based cancer diagnostics and markers.

Biodesix this week received an EU CE Mark for its Veristrat specimen collection and shipping kit, allowing the company to make Veristrat results available to physicians in the EU and other countries recognizing the CE Mark.

Quest Offering Lynch Syndrome Genetic Panel Testing in US
Quest Diagnostics has launched a new testing service for gauging patients' risk of Lynch Syndrome, or hereditary nonpolyposis colorectal cancer.

Biodesix said this week that it has closed a structured debt financing with Capital Royalty Partners that provides the company with up to $20 million.

NEW YORK (GenomeWeb News) – Biodesix said today that it has expanded a series E offering that raised $8.3 million in December.

NEW YORK (GenomeWeb News) – Biodesix today said that it has closed an $8.3 million Series E round of private financing.

Biodesix Raises $4M

NEW YORK (GenomeWeb News) – Molecular diagnostics company Biodesix said in a regulatory document that it has raised about $4 million in a private financing.

Pages

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.